DUBLIN, June 26 /PRNewswire-FirstCall/ --
- Singapore Laboratory Testing Increases by 149% in Past Six Months
ICON plc (NASDAQ:ICLR: ISIN: IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has moved its Singapore central laboratory to a new, larger facility located at Loyang Way, Eastern Singapore. The new laboratory meets the growth in demand for ICON Central Laboratories' services in Singapore, which has increased by 149% over the past six months. The larger facility also enables ICON Central Laboratories to expand its test menu offerings in the region to include increased esoteric testing as well as flow cytometry, molecular diagnostics and biomarkers, to complement the services of ICON's other wholly-owned central laboratories in Europe, India and the United States.
"As ICON celebrates its tenth year of operation in Singapore, our move to a larger laboratory signals our continued commitment to the region," commented Bob Scott-Edwards, President, ICON Central Laboratories. "Singapore has become a regional hub for drug development in Asia-Pacific and we now have the capacity, the range of testing services and, above all, a highly experienced team of lab professionals to support the growth of clinical trials in the region."
ICON Central Laboratories Singapore supports all major therapeutic areas, including cardiovascular, oncology, endocrinology and metabolism, and virology. The laboratory serves as a regional hub for test samples from Australia, New Zealand, South Korea, Malaysia, Singapore, Taiwan, Japan, Thailand, Hong Kong, China and Indonesia. ICON Central Laboratories Singapore received CAP (College of American Pathologists) accreditation in March 2009, ensuring the highest standards of excellence in laboratory services.
About ICON Central Laboratori
|SOURCE ICON plc|
Copyright©2009 PR Newswire.
All rights reserved